These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18058459)

  • 1. Epigenetic regulation as a new target for breast cancer therapy.
    Stearns V; Zhou Q; Davidson NE
    Cancer Invest; 2007 Dec; 25(8):659-65. PubMed ID: 18058459
    [No Abstract]   [Full Text] [Related]  

  • 2. Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells.
    Cras A; Darsin-Bettinger D; Balitrand N; Cassinat B; Soulié A; Toubert ME; Delva L; Chomienne C
    Oncogene; 2007 Jun; 26(27):4018-24. PubMed ID: 17213810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status.
    Travaglini L; Vian L; Billi M; Grignani F; Nervi C
    Int J Biochem Cell Biol; 2009 Jan; 41(1):225-34. PubMed ID: 18789398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic information and estrogen receptor alpha expression in breast cancer.
    Giacinti L; Claudio PP; Lopez M; Giordano A
    Oncologist; 2006 Jan; 11(1):1-8. PubMed ID: 16401708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eliminating epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor negative breast cancer cells.
    Fleury L; Gerus M; Lavigne AC; Richard-Foy H; Bystricky K
    Oncogene; 2008 Jul; 27(29):4075-85. PubMed ID: 18317449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromatin-remodelling mechanisms in cancer.
    Lafon-Hughes L; Di Tomaso MV; Méndez-Acuña L; Martínez-López W
    Mutat Res; 2008; 658(3):191-214. PubMed ID: 18403253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
    Mai A; Altucci L
    Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic interplay between histone modifications and DNA methylation in gene silencing.
    Vaissière T; Sawan C; Herceg Z
    Mutat Res; 2008; 659(1-2):40-8. PubMed ID: 18407786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors as anti-neoplastic agents.
    Batty N; Malouf GG; Issa JP
    Cancer Lett; 2009 Aug; 280(2):192-200. PubMed ID: 19345475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells.
    Rahim R; Strobl JS
    Anticancer Drugs; 2009 Sep; 20(8):736-45. PubMed ID: 19584707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning.
    Hinshelwood RA; Melki JR; Huschtscha LI; Paul C; Song JZ; Stirzaker C; Reddel RR; Clark SJ
    Hum Mol Genet; 2009 Aug; 18(16):3098-109. PubMed ID: 19477956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERas oncogene expression and epigenetic regulation by histone acetylation in human cancer cells.
    Yasuda K; Yashiro M; Sawada T; Ohira M; Hirakawa K
    Anticancer Res; 2007; 27(6B):4071-5. PubMed ID: 18225573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
    Emanuele S; Lauricella M; Tesoriere G
    Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.
    Epping MT; Bernards R
    Int J Biochem Cell Biol; 2009 Jan; 41(1):16-20. PubMed ID: 18765293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic mechanisms of breast cancer: an update of the current knowledge.
    Karsli-Ceppioglu S; Dagdemir A; Judes G; Ngollo M; Penault-Llorca F; Pajon A; Bignon YJ; Bernard-Gallon D
    Epigenomics; 2014; 6(6):651-64. PubMed ID: 25531258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone acetylation characterizes chromatin presetting by NF1 and Oct1 and enhances glucocorticoid receptor binding to the MMTV promoter.
    Astrand C; Belikov S; Wrange O
    Exp Cell Res; 2009 Sep; 315(15):2604-15. PubMed ID: 19463811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Epigenetics in hematological disorders].
    Furukawa Y
    Rinsho Ketsueki; 2008 Oct; 49(10):1472-82. PubMed ID: 18833931
    [No Abstract]   [Full Text] [Related]  

  • 18. Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni.
    Dubois F; Caby S; Oger F; Cosseau C; Capron M; Grunau C; Dissous C; Pierce RJ
    Mol Biochem Parasitol; 2009 Nov; 168(1):7-15. PubMed ID: 19538992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of epigenetic modifications and chromatin remodeling in spinal muscular atrophy.
    Lunke S; El-Osta A
    J Neurochem; 2009 Jun; 109(6):1557-69. PubMed ID: 19383090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenome: a new target in cancer therapy.
    Giacinti L; Vici P; Lopez M
    Clin Ter; 2008; 159(5):347-60. PubMed ID: 18998037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.